

IPR2018-00943
Patent No. 7,919,499
Petitioner's Reply to Patent Owner's Response
Attorney Docket: AMNEAL 7.1R-005

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

AMNEAL PHARMACEUTICALS LLC,
Petitioner,

v.

ALKERMES PHARMA IRELAND LIMITED,
Patent Owner.

Case IPR2018-00943
Patent No. 7,919,499 B2

**PETITIONER'S REPLY TO
PATENT OWNER'S RESPONSE**

5892704_1.docx

TABLE OF CONTENTS

TABLE OF AUTHORITIES iii

PETITIONER’S EXHIBIT LIST iv

I. INTRODUCTION 1

II. CLAIM CONSTRUCTION 2

 A. “Single Injection” 2

 B. “The Serum AUC Of Naltrexone... Achieved By 50 mg/Day Oral Administration” 3

 C. “Initial Oral Dose Of Naltrexone” 4

III. THE CLAIMS ARE ANTICIPATED 4

 A. Grounds 1 And 2: Comer And Nuwayser 4

 1. A POSA Can Calculate AUC 7

 2. Photoshop Is An Appropriate Technique..... 7

 3. Time Zero (“T_{zero}”)..... 8

 4. Sampling Frequency 9

 5. Prior Dosing 10

 6. Starting With Cmax 11

 7. Single Injection 11

 8. The Claimed AUC Differential..... 12

 9. Comer Teaches “Treating” 12

 B. Claims 10 And 11 Are Anticipated 14

 1. Alcohol Dependency 14

 2. Administration Without An Initial Oral Dose 14

IV.	THE CLAIMS ARE OBVIOUS.....	15
A.	Grounds 3 And 4: The Claims Are Obvious Over Comer, Nuwayser, Rubio, And Wright	15
1.	The Combination Teaches A Method of Parenterally Administering Naltrexone Within The Claimed Dose Range	15
2.	Alkermes' Criticisms	17
3.	Claims 2, 6-9, And 11 Are Obvious	17
a.	Claims 2 And 6	17
b.	Claims 7-9.....	18
c.	Claims 2 And 11	18
B.	Ground 5: The Claims Are Obvious Over Nuwayser, Kranzler, Rubio, And Wright	19
C.	Ground 6: Alkermes' 10-K And The Vivitrex™ Specimen Were Both Publicly Accessible and Render The Claims Obvious	19
V.	ALKERMES' SECONDARY CONSIDERATIONS FAIL	21
A.	Alkermes Fails To Prove Any Nexus	21
B.	Providing A 3x AUC Differential Does Not Satisfy A Long-Felt But Unresolved Need.....	23
C.	Vivitrol's Praise Has Nothing To Do With An Increase In AUC	23
VI.	CONCLUSION.....	24

TABLE OF AUTHORITIES

	Page(s)
Cases	
<i>Alcon Research, Ltd. v. Apotex Inc.</i> , 687 F.3d 1362 (Fed. Cir. 2012)	16
<i>Baldwin Graphic Sys., Inc. v. Siebert, Inc.</i> , 512 F.3d 1338,1342 (Fed. Cir. 2008)	2
<i>Bristol-Myers Squibb Co. v. Ben Venue Labs., Inc.</i> , 246 F.3d 1368 (Fed. Cir. 2001)	6
<i>Brown & Williamson Tobacco Corp. v. Phillip Morris Inc.</i> , 229 F.3d 1120 (Fed. Cir. 2000)	21
<i>Custom Accessories, Inc. v. Jeffrey-Allan Indus.</i> , 807 F.2d 955 (Fed. Cir. 1986)	20
<i>In re Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011)	6, 12
<i>Kimberly-Clark Corp. v. Johnson & Johnson</i> , 745 F.2d 1437 (Fed. Cir. 1984)	20
<i>Meds. Co. v. Mylan Inc.</i> , No. 11-cv-1285, 2014 U.S. Dist. LEXIS 38714 (N.D. Ill. Mar. 25, 2014).....	22
<i>Novartis AG v. Torrent Pharms., Ltd.</i> , 853 F.2d 1316 (Fed. Cir. 2017)	22
<i>In re Omeprazole</i> , 483 F.3d 1364 (Fed. Cir. 2007)	6
<i>Par Pharm., Inc. v. TWi Pharms., Inc.</i> , 773 F.3d 1186 (Fed. Cir. 2014)	16
<i>Santarus, Inc. v. Par Pharm, Inc.</i> , 694 F.3d 1344 (Fed. Cir. 2012)	17
<i>Therasense, Inc. v. Becton, Dickinson & Co.</i> , 593 F.3d 1289 (Fed. Cir. 2010), <i>vacated on other grounds</i> , 374 F. App'x 35 (Fed. Cir. 2010)	22

PETITIONER'S EXHIBIT LIST

Exhibit #	Reference
1001	U.S. Patent No. 7,919,499 (“the ’499 Patent”)
1002	U.S. Serial Number 11/083,167, Office Action, May 5, 2009
1003	Serial No. 11/083,167, Declaration Under 37 C.F.R. § 1.132 of Elliot Ehrich (undated)
1004	U.S. Serial Number 11/083,167, Amendment and Response, Oct. 5, 2009
1005	U.S. Serial Number 11/083,167, Office Action, Jan. 6, 2010
1006	U.S. Serial Number 11/083,167, Amendment and Response, Apr. 5, 2010
1007	U.S. Serial Number 11/083,167, Final Rejection, July 20, 2010
1008	U.S. Serial Number 11/083,167, Amendment After Final, Oct. 20, 2010
1009	U.S. Serial Number 11/083,167, Notice of Allowance, Dec. 1, 2010
1010	Sandra D. Comer <i>et al.</i> , <i>Depot naltrexone: long-lasting antagonism of the effects of heroin in humans</i> , 159(4) <i>Psychopharmacology</i> (Feb. 2002), at 351-360
1011	Henry R. Kranzler <i>et al.</i> , <i>Sustained-Release Naltrexone for Alcoholism Treatment: A Preliminary Study</i> , 22(5) <i>Alcoholism: Clinical and Experimental Research</i> (Aug. 1998), at 1074-79
1012	C.N. Chiang <i>et al.</i> , <i>Clinical Evaluation of A Naltrexone Sustained-Release Preparation</i> , 16 <i>Drug & Alcohol Dependence</i> (1985), at 1-8
1013	T.N. Alim <i>et al.</i> , <i>Tolerability Study of A Depot Form of Naltrexone Substance Abusers</i> , <i>Problems of Drug Dependence</i> , 1994: Proceedings of the 56th Annual Scientific Meeting, The College on Problems of Drug Dependence, Inc., Vol. II: Abstracts, National Institute on Drug Abuse Research Monograph 153 (1995), at 253
1014	U.S. Patent No. 7,157,102 (“the ’102 Patent” or “Nuwayser”)
1015	U.S. Patent No. 6,306,425 (“Tice”)

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.